Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colony‐stimulating factor (rhG‐CSF): a randomized evaluation of different doses of rhG‐CSF
- 1 February 2002
- journal article
- clinical trial
- Published by Wiley in British Journal of Haematology
- Vol. 116 (2) , 468-474
Abstract
Summary. To date, no randomized study has compared different doses of recombinant human granulocyte colony‐stimulating factor (rhG‐CSF) following submyeloablative mobilization chemotherapy. Therefore, we evaluated the effect of different doses of rhG‐CSF following mobilization chemotherapy on yields of CD34+ peripheral blood stem cells (PBSC). Fifty patients were randomized to receive 8 (n = 25) versus 16 µg/kg/d (n = 25) of rhG‐CSF following mobilization chemotherapy. The median number of CD34+ cells collected after 8 µg/kg/d of rhG‐CSF was 2·36 × 106/kg (range, 0·21–7·80), compared with 7·99 (2·76–14·89) after 16 µg/kg/d (P < 0·001). Twenty out of 25 (80%) patients in the low‐dose and 23 out of 25 (92%) in the high‐dose rhG‐CSF arm underwent high‐dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT). Median days to white blood cell engraftment in patients mobilized with 8 µg/kg and 16 µg/kg of rhG‐CSF were 12 (10–20) and 9 (8–11) respectively (P < 0·001). There was no difference between the two groups regarding the other parameters of peritransplant morbidity: days to platelet engraftment (P = 0·10), number of red blood cell (P = 0·56) and platelet transfusions (P = 0·22), days of total parenteral nutrition requirement (P = 0·84), fever (P = 0·93) and antibiotics (P = 0·77), and number of different antibiotics used (P = 0·58). These data showed that higher doses of rhG‐CSF following submyeloablative mobilization chemotherapy were associated with a clear dose–response effect based on the collected cell yields. Based on the parameters of peritransplant morbidity, 8 µg/kg/d was as effective as 16 µg/kg/d except for a rapid neutrophil engraftment in the high‐dose arm. Therefore, in routine clinical practice, despite some advantage in the use of higher doses of rhG‐CSF, lower doses may be used for PBSC collections following chemotherapy‐based mobilization regimens in this cost‐conscious era.Keywords
This publication has 14 references indexed in Scilit:
- A phase I dose escalation study of high-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation (PBSCT) in patients with solid tumors and hematologic malignanciesBone Marrow Transplantation, 2000
- Peripheral Blood Stem Cell Mobilization for High-Dose ChemotherapyJournal of Hematotherapy, 1999
- Phase I–II evaluation of rapid sequence tandem high-dose melphalan with peripheral blood stem cell support in patients with multiple myelomaBone Marrow Transplantation, 1998
- Mobilization and harvesting of peripheral blood stem cells: randomized evaluations of different doses of filgrastimBritish Journal of Haematology, 1998
- Optimization of Peripheral Blood Stem Cell MobilizationStem Cells, 1996
- High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.Journal of Clinical Oncology, 1994
- Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG‐CSF): an analysis of factors correlating with the tempo of engraftment after transplantationBritish Journal of Haematology, 1994
- High-dose therapy and peripheral blood progenitor cell transplantation: effects of recombinant human granulocyte-macrophage colony-stimulating factor on the autograftBlood, 1994
- Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteriaInvestigational New Drugs, 1992
- Regimen-related toxicity in patients undergoing bone marrow transplantation.Journal of Clinical Oncology, 1988